Clinical and Pharmacoeconomic Results of the Usage of Various HIV Reverse Transcriptase Inhibitors in the Schemes of Antiretroviral Therapy of Patients Receiving Therapy for the Chronic Hepatitis C Virus

Abstract

Efficacy, safety, and economical aspects of treatment with abacavir, zidovudine, stavudine, and phosphazide in the schemes of antiretroviral therapy of the HIV-infected patients receiving therapy for hepatitis C virus were tested. Clinical, immunological, and virologic efficacy of treatment and dynamics of hemoglobin, thrombocytes, and alanine aminotransferase as markers of common adverse events recorded at the start of the antiviral therapy of chronic hepatitis C and after 4, 8, 12, 24, 48 weeks of the treatment were evaluated. The usage of these drugs in the schemes of antiretroviral therapy exhibited efficacy, high tolerability and safety for all HIV reverse transcriptase inhibitors.

Keywords

• hiv/hepatitis c virus coinfection
• anemia
• thrombocytosis
• thrombocytopenia
• polyneuropathy
• lipodystrophy
• immunological and virologic efficacy
• phosphazide